SCHEMBL2091508

SCHEMBL2091508

Cc1coc2ccc(Cl)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.50
KCNA3 P22001 2/20 0.44
AHR P35869 5/20 0.42
MCL1 Q07820 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP2A6 P11509 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
LMNA P02545 2/20 0.39
CYP3A4 P08684 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
MAOB P27338 3/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
NFKB1 P19838 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5679743 0.85 PTPN1 (0.61) PTPN1ALDH1A1KDM4EADORA3MAOB
SCHEMBL2092632 0.83 KCNA3 (0.44) PTPN1KCNA3AHRMCL1ALDH1A1
SCHEMBL20274092 0.78 PTPN1 (0.53) PTPN1AHRALDH1A1KDM4ELMNA
SCHEMBL4454971 0.78 ALDH1A1 (0.47) KCNA3ALDH1A1KDM4ECYP3A4MAOB
SCHEMBL718267 0.75 PTPN1 (0.50) PTPN1KCNA3ALDH1A1KDM4ECYP3A4
SCHEMBL18936105 0.75 ALDH1A1 (0.42) KCNA3ALDH1A1KDM4ECYP3A4HSD17B10
SCHEMBL789581 0.75 ALDH1A1 (0.51) PTPN1KCNA3AHRALDH1A1KDM4E
SCHEMBL31231895 0.75 PTPN1 (0.50) PTPN1KCNA3ALDH1A1KDM4ECYP3A4
SCHEMBL5341052 0.75 NPC1 (0.44) KCNA3ALDH1A1KDM4ECYP3A4HSD17B10
SCHEMBL31405756 0.75 ALDH1A1 (0.51) PTPN1KCNA3AHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN claimed
CN-119176813-A Tricyclic heterocyclic compound with FGFR inhibition effect, pharmaceutical composition containing tricyclic heterocyclic compound and application of pharmaceutical composition 上海科恩泰生物医药科技有限公司 2024-12-24 CN disclosed
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
CN-113122061-A Quantum dot ink and preparation method of quantum dot film TCL集团股份有限公司 2021-07-16 CN disclosed
US-10562897-B2 Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators JANSSEN PHARMACEUTICA NV (BE) 2020-02-18 US disclosed
US-10246454-B2 Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators JANSSEN PHARMACEUTICA NV (BE) 2019-04-02 US disclosed
US-9783522-B2 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-10-10 US disclosed
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-16 US disclosed
CN-105492437-A Substituted benzofuranyl and benzoxazolyl compounds and uses thereof KARYOPHARM THERAPEUTICS INC 2016-04-13 CN disclosed
US-20150353544-A1 NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-12-10 US disclosed
CN-1505514-A Combination of aldose reductase inhibitors with cyclooxygenase-2 inhibitors �Ʒ� 2004-06-16 CN disclosed
EP-1392310-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS Pfizer Products Inc. (US) 2004-03-03 EP disclosed
EP-1373259-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS Pfizer Products Inc. (US) 2004-01-02 EP disclosed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 US disclosed
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents TOM NORMA J (US) 2003-08-28 US disclosed
WO-2003057691-A1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2003-07-17 WO disclosed
US-6579879-B2 Pyridazinone aldose reductase inhibitors PFIZER INC 2003-06-17 US disclosed
WO-2002087584-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 WO disclosed
WO-2002079198-A1 PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS PFIZER PRODUCTS INC. (US) 2002-10-10 WO disclosed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246454-B2 Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators BACE1, BACE2, PSEN1 PTPN1 3664/4885KCNA3 1423/4885AHR 2104/4885
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF ENPP2, ATXN2, ATXN2L PTPN1 393/4885KCNA3 2458/4885AHR 1774/4885
US-20150353544-A1 NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 PTPN1 3983/4885KCNA3 1191/4885AHR 2576/4885
US-20030162784-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 PTPN1 1807/4885KCNA3 1308/4885AHR 3095/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 PTPN1 1843/4885KCNA3 1881/4885AHR 2958/4885
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents ALDOA, AKR1B1, DPYD PTPN1 4027/4885KCNA3 1628/4885AHR 2569/4885
US-10562897-B2 Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators BACE1, BACE2, PSEN1 PTPN1 3664/4885KCNA3 1423/4885AHR 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.